Myllia Biotechnology GmbH

Next-gen CRISPR screens to fast-forward drug discovery

+4319346880200 +436767420974 info@myllia.com https://myllia.com/

Am Kanal 27

1110 Wien

Mo	08:00-18:00
Di	08:00-18:00
Mi	08:00-18:00
Do	08:00-18:00
Fr	08:00-18:00
Sa	geschlossen
So	geschlossen

Über uns

2018 gegründet

25 Mitarbeiter

Myllia Biotechnology is a CRISPR screening biotech company founded in Vienna, Austria in 2018. At Myllia, we combine CRISPR screening with single-cell RNA sequencing, leveraging two transformative technologies to enable genetic screening for complex phenotypes.

We utilize the CRISPR screening (CROP-Seq) workflow to map the impact of thousands of genetic perturbations on the global transcriptome at single-cell resolution, thus effectively establishing a paradigm for next-generation CRISPR screens. We work with clients in the industry and offer customized or genome-scale CRISPR knockout and CRISPR interference screens based on a fee-for-service model.

Our powerful approach has broad applications in identifying novel drug targets or elucidating unknown mechanisms of actions (MoA) of drugs. Notably, we offer single-cell CRISPR screens in cancer cells and primary cells, including primary human T cells to support biotech and pharma companies striving to develop novel CAR-T and TCR-T cell therapeutics.

Produkte und Leistungen

Myllia performs CRISPR screening projects for biotech and pharma clients. We perturb cells with CRISPR KO, CRISPR interference or CRISPR activation and combine it with various read-outs including fitness, flow cytometry or single-cell RNA sequencing.

We employ customized CRISPR KO, CRISPR interference or CRISPR activation screens at large scale in different cellular models and couple it to various read-outs including dropout fitness, flow cytometry and single-cell transcriptomics (RNA sequencing).

The CROP-seq workflow allows to map the impact of thousands of genetic perturbations at single-cell resolution, thus establishing a paradigm for next-generation CRISPR screens. Our powerful approach facilitates functional genomics in CRISPR-ready cancer cell lines and primary human T cells. Briefly, CRISPR screens fast-forward drug discovery across many applications:

1 - Identify and/or validate drug targets in CRISPR-ready cancer cells and primary human T cells
2 - Identify modulators of CAR-T or TCR-T cell therapies to boost T cell potency
3 - Unravel the molecular mechanism of disease-associated genes and immune pathways
4 - Decipher the mechanism of action (MoA) of drugs